Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Details for Patent: 6,546,929

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 6,546,929 protect, and when does it expire?

Patent 6,546,929 protects EXUBERA and is included in one NDA.

This patent has one hundred and four patent family members in fifty-four countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.

Summary for Patent: 6,546,929
Title: Dry powder dispersing apparatus and methods for their use
Abstract:The invention provides various apparatus and methods for aerosolizing a powdered medicament. In one exemplary embodiment, an apparatus includes a pressurization cylinder, and a piston which is slidable within the cylinder to pressurize a gas. A handle is coupled to the piston and is movable between an extended position and a home position to pressurize the gas. An aerosolizing mechanism is included and is configured to aerosolize a powdered medicament that is held within a receptacle with pressurized gas from the cylinder. A carriage assembly is included to receive the receptacle and to couple the receptacle to the aerosolizing mechanism. A first and a second interlock are operably engageable with the carriage assembly to prevent coupling of the receptacle with the aerosolization mechanism. The first interlock is released to allow movement of the carriage upon movement of the handle to the extended position. The second interlock remains engaged if the receptacle is only partially inserted into the carriage assembly.
Inventor(s): Burr; John D. (Redwood City, CA), Smith; Adrian E. (Belmont, CA), Hall; Randy K. (Mountain View, CA), Snyder; Herman (Belmont, CA), Schuler; Carlos (Cupertino, CA), Axford; George S. (San Mateo, CA), Ray; Charles (Foster City, CA)
Assignee: Inhale Therapeutic Systems, Inc. (San Carlos, CA)
Application Number:09/873,946
Patent Claim Types:
see list of patent claims
Use; Device; Delivery;

Drugs Protected by US Patent 6,546,929

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pfizer EXUBERA insulin recombinant human POWDER;INHALATION 021868-001 Jan 27, 2006 DISCN No No   Start Trial   Start Trial METHOD OF ADMINISTERING INSULIN VIA INHALATION   Start Trial
Pfizer EXUBERA insulin recombinant human POWDER;INHALATION 021868-002 Jan 27, 2006 DISCN No No   Start Trial   Start Trial METHOD OF ADMINISTERING INSULIN VIA INHALATION   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.